Alnylam Inks License, RNAi Rx-Discovery Deal With Roche Worth Up to $1 Billion

The deal also calls for Roche to acquire Alnylam’s German subsidiary, a financial burden the RNAi company has been required to shoulder as part of a 2002 licensing deal.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories